Long-segment thoracoabdominal aortic coarctation in a child with Down syndrome

Vasconcelos, Vladimir; Cal, Ruy Guilherme Rodrigues; Gomes, Adriano Luis; Aguiar, Simone S.; Camargo, Maria Fernanda Carvalho de; Baptista-Silva, José Carlos Costa

doi:10.1016/j.jvsc.2015.04.011

Cited by 2 publications

(1 citation statement)

References 17 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data highlight differences in the referral populations, as most reports originate from specialist single centers. Cases of MAS have also been reported in the Middle East, North Africa, South and Far-East Asia, and Central and South America [8,[13][14][15][16]. It remains difficult to ascertain the true burden of MAS owing to the paucity of population-based national and international registries.…”

Section: Epidemiologymentioning

confidence: 99%

Middle aortic syndrome in children and adolescents

Musajee¹,

Gasparini²,

Stewart³

et al. 2022

gcsp

View full text Add to dashboard Cite

Middle aortic syndrome is a rare form of renovascular disease that may present with severe hypertension during childhood. Narrowing of the abdominal aorta is often associated with narrowing of the renal and/or other visceral arteries and may be secondary to specific genetic syndromes. Following the optimization of blood pressure control, significant aortic narrowing often requires invasive management, including endovascular and surgical intervention. In younger children, endovascular therapy may be attempted in the first instance to acutely reduce the pressure gradient across the narrowing; however, a sustained benefit is rare. Once the child has grown to accommodate a graft of an adequate size, surgical therapy is indicated for patients in whom medical and/or endovascular management has not resulted in adequate blood pressure control. It is critical that individuals with middle aortic syndrome be managed by an experienced multidisciplinary team that includes medical, endovascular, and surgical expertise that can provide long-term care to monitor for recurrent hypertension and evidence of end-organ damage.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Middle aortic syndrome in children and adolescents

Musajee¹,

Gasparini²,

Stewart³

et al. 2022

gcsp

View full text Add to dashboard Cite

show abstract

Research progress of moyamoya disease combined with renovascular hypertension

et al. 2022

View full text Add to dashboard Cite

Moyamoya disease (MMD) is an idiopathic cerebrovascular disease which was first described by Suzuki and Takaku in 1969. Moyamoya disease is a non-atherosclerotic cerebrovascular structural disorder. MMD has been found all over the world, especially in Japan, Korea, and China. In recent years, many reports pointed out that the changes of vascular stenosis in patients with moyamoya disease occurred not only in intracranial vessels, but also in extracranial vessels, especially the changes of renal artery. Renovascular hypertension (RVH) is considered to be one of the important causes of hypertension in patients with moyamoya disease. The pathogenesis of moyamoya disease combined with renovascular hypertension is still unclear, and the selection of treatment has not yet reached a consensus. This article reviews the latest research progress in epidemiology, RNF213 gene, pathomorphology, clinical characteristics and treatment of moyamoya disease combined with renovascular hypertension, in order to provide reference for clinical workers.

show abstract

Long-segment thoracoabdominal aortic coarctation in a child with Down syndrome

Cited by 2 publications

References 17 publications

Middle aortic syndrome in children and adolescents

Middle aortic syndrome in children and adolescents

Research progress of moyamoya disease combined with renovascular hypertension

Contact Info

Product

Resources

About